AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
NextCure Inc (NASDAQ:NXTC)
0.48875 USD
+0.009 1.759%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.4803 |
|---|---|
| Change | +0.009 1.759% |
| 52 W H/L (in USD) | 2.570/0.980 |
| EBITDA (in USD) | -62.814M |
| PE Ratio | -- |
| Volume | 34934 |
| Diluted Eps TTM | -2.22 |
| Total Assets (in USD) | 129.418M |
|---|---|
| Total Liabilities (in USD) | 14.997M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 13.082M |
| Market Cap (in USD) | 42.240 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -54.199M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
9000 Virginia Manor Road, Beltsville, MD, United States, 20705
240 399 4900
Employees: 82
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael S. Richman MSBA | Co-Founder, CEO, Pres & Director | 1961 |
| 2. | Dr. Solomon Langermann Ph.D. | Chief Scientific Officer | 1960 |
| 3. | Dr. Han Myint FACP, M.D. | Chief Medical Officer | 1953 |
| 4. | Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1958 |
| 5. | Mr. Steven P. Cobourn CPA, CPA | Chief Financial Officer | 1963 |
| 6. | Dr. Timothy Mayer Ph.D. | Chief Operating Officer | 1965 |
| 7. | Mr. Sourav Kundu Ph.D. | Sr. VP of Devel. & Manufacturing | 1960 |
| 8. | Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director | 1961 |
| 9. | Mr. Steven P. Cobourn CPA | Chief Financial Officer | 1963 |
| 10. | Mr. Kevin G. Shaw | General Counsel | 1974 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.814 1.173% | 69.98 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.003 0.004% | 69.32 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+0.030 0.006% | 486.27 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-7.260 1.145% | 630.51 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -74.733M | -69.389M | -36.603M | -33.737M | -22.799M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -69.433M | -69.389M | -33.19M | -33.737M | -22.799M |
| Selling General Administrative | 21.71M | 20.573M | 17.049M | 9.613M | 3.409M |
| Gross Profit | - | - | 22.378M | 6.347M | -19.787M |
| Reconciled Depreciation | 4.124M | 7.196M | 3.413M | 2.688M | 1.677M |
| Ebit | -80.033M | -70.765M | -44.638M | -37.482M | -23.196M |
| Ebitda | -75.909M | -63.569M | -41.225M | -34.794M | -21.519M |
| Depreciation And Amortization | 4.124M | 7.196M | 3.413M | 2.688M | 1.677M |
| Operating Income | -75.909M | -70.765M | -41.225M | -37.482M | -23.196M |
| Other Operating Expenses | 75.909M | 70.765M | 63.603M | 43.829M | 23.196M |
| Interest Expense | 5.3M | 1.376M | 0M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | 3.745M | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | -5.3M | -1.376M | -3.413M | -3.745M | 0.397M |
| Total Revenue | 0M | 0M | 22.378M | 6.347M | 0M |
| Total Operating Expenses | 75.909M | 70.765M | 63.603M | 43.829M | 23.196M |
| Cost Of Revenue | - | - | - | 34.216M | 19.787M |
| Total Other Income Expense Net | 1.176M | 1.376M | 4.622M | 3.745M | 0.397M |
| Net Income From Continuing Ops | -74.733M | -69.389M | -36.603M | -33.737M | -22.799M |
| Net Income Applicable To Common Shares | -74.733M | -69.389M | -36.603M | -33.737M | -22.799M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 129.418M | 184.161M | 242.386M | 306.644M | 356.168M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.626M | 4.072M | 8.187M | 2.824M | 3.684M |
| Total Liab | 14.997M | 16.631M | 9M | 12.923M | 34.684M |
| Total Stockholder Equity | 114.421M | 167.53M | 233.386M | 293.721M | 321.484M |
| Other Current Liab | 3.897M | 4.339M | 4.666M | 4.757M | 4.951M |
| Common Stock | 0.028M | 0.028M | 0.028M | 0.028M | 0.027M |
| Capital Stock | 0.028M | 0.028M | 0.028M | 0.028M | 0.027M |
| Retained Earnings | -324.482M | -261.759M | -187.026M | -117.637M | -81.034M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 3.265M | 0.577M | 2.857M | 4.083M |
| Cash | 13.082M | 26.63M | 12.337M | 32.772M | 34.091M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 6.883M | 9.127M | 6.608M | 10.325M | 15.042M |
| Current Deferred Revenue | - | - | - | - | 6.428M |
| Net Debt | -6.477M | -19.507M | -12.337M | -29.299M | -28.956M |
| Short Term Debt | 0.656M | 0.518M | - | 1.667M | 1.802M |
| Short Long Term Debt | - | - | - | 1.667M | 1.667M |
| Short Long Term Debt Total | 6.605M | 7.123M | - | 3.473M | 5.135M |
| Other Stockholder Equity | 439.097M | 430.755M | 421.047M | 410.551M | 46.361M |
| Property Plant Equipment | - | 11.897M | 13.992M | 15.809M | 12.09M |
| Total Current Assets | 112.725M | 163.983M | 227.817M | 287.978M | 339.995M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 95.217M | 133.281M | 207.254M | 250.676M | 300.514M |
| Net Receivables | 0.8M | - | - | - | - |
| Long Term Debt | - | - | - | 1.806M | 3.333M |
| Inventory | - | - | - | - | - |
| Accounts Payable | 2.33M | 4.27M | 1.942M | 3.901M | 1.861M |
| Accumulated Other Comprehensive Income | -0.222M | -1.494M | -0.663M | 0.779M | -0.038M |
| Non Currrent Assets Other | 1.882M | 3.265M | 0.577M | 2.857M | 4.083M |
| Non Current Assets Total | 16.693M | 20.178M | 14.569M | 18.666M | 16.173M |
| Capital Lease Obligations | 6.605M | 7.123M | - | - | 0.135M |
| Long Term Debt Total | - | - | - | 1.806M | 3.333M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 67.979M | 38.961M | 50.655M | -303.923M | -300.552M |
| Total Cashflows From Investing Activities | 67.979M | 36.601M | 43.523M | -303.923M | -3.063M |
| Total Cash From Financing Activities | 0.2M | -3.265M | -1.415M | 243.043M | 121.417M |
| Net Income | -74.733M | -69.389M | -36.603M | -33.737M | -22.799M |
| Change In Cash | 14.293M | -23.908M | -2.846M | -96.503M | 126.346M |
| Begin Period Cash Flow | 12.337M | 36.284M | 39.13M | 135.633M | 9.287M |
| End Period Cash Flow | 26.63M | 12.376M | 36.284M | 39.13M | 135.633M |
| Total Cash From Operating Activities | -53.886M | -57.244M | -44.954M | -35.623M | 7.992M |
| Depreciation | 4.124M | 7.196M | 3.413M | 2.688M | 1.677M |
| Other Cashflows From Investing Activities | - | - | - | -300.552M | 0M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | 0.2M | 0.208M | 0.112M | 238.503M | 122.227M |
| Other Cashflows From Financing Activities | 0.134M | 0.208M | 43.523M | 4.54M | 121.813M |
| Capital Expenditures | 2.116M | 2.36M | 7.132M | 3.371M | 3.063M |
| Change In Working Capital | 3.725M | -5.339M | -19.675M | -6.46M | 28.851M |
| Other Non Cash Items | 3.49M | 51.105M | 27.625M | -205.926M | -90.34M |
| Free Cash Flow | -56.002M | -59.604M | -52.086M | -38.994M | 4.929M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 613827 |
| 2. | Federated Hermes MDT Small Cap Growth IS | 1 year ago | 315180 |
| 3. | Federated Hermes MDT SCG Institutional | 1 year ago | 315180 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 201978 |
| 5. | Vanguard Explorer Inv | 1 year ago | 171519 |
| 6. | BlackRock Advantage Small Cap Core Instl | 11 months ago | 169789 |
| 7. | Delaware Healthcare I | 1 year ago | 150000 |
| 8. | Fidelity Extended Market Index | 1 year ago | 94203 |
| 9. | LUNIS Biotech Growth Opp Fd I a | 1 year ago | 85000 |
| 10. | Bridgeway Ultra-Small Company Market | 1 year ago | 65900 |
| 11. | iShares Micro-Cap ETF | 11 months ago | 48303 |
| 12. | BlackRock Extended Mkt Composite | 1 year ago | 29931 |
| 13. | Fidelity Total Market Index | 1 year ago | 28995 |
| 14. | BlackRock Extended Equity Market K | 1 year ago | 26122 |
| 15. | Fidelity Series Total Market Index | 1 year ago | 24411 |
| 16. | Fidelity Nasdaq Composite Index | 1 year ago | 15140 |
| 17. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 14558 |
| 18. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 13302 |
| 19. | Northern Trust Extended Eq Market Idx | 1 year ago | 13302 |
| 20. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 11692 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Orbimed Advisors, LLC | 1 year ago | 2711013 |
| 2. | Sofinnova Ventures | 1 year ago | 2671856 |
| 3. | Logos Global Management LP | 1 year ago | 1925000 |
| 4. | Millennium Management LLC | 1 year ago | 1134078 |
| 5. | Vanguard Group Inc | 1 year ago | 987324 |
| 6. | BlackRock Inc | 1 year ago | 890102 |
| 7. | Cable Car Capital LLC | 1 year ago | 615878 |
| 8. | Long Focus Capital Management, LLC | 1 year ago | 556105 |
| 9. | Acadian Asset Management LLC | 1 year ago | 488440 |
| 10. | Assenagon Asset Management SA | 1 year ago | 426717 |
| 11. | Acuitas Investments, LLC | 1 year ago | 372799 |
| 12. | Federated Hermes Inc | 1 year ago | 327847 |
| 13. | BML Capital Management LLC | 1 year ago | 306465 |
| 14. | Renaissance Technologies Corp | 1 year ago | 293315 |
| 15. | CARDIFF PARK ADVISORS, LLC | 1 year ago | 262000 |
| 16. | Geode Capital Management, LLC | 1 year ago | 174707 |
| 17. | Macquarie Group Ltd | 1 year ago | 150000 |
| 18. | Sio Capital Management, LLC | 1 year ago | 130000 |
| 19. | Bridgeway Capital Management, LLC | 1 year ago | 94600 |
| 20. | Dimensional Fund Advisors, Inc. | 1 year ago | 85853 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
